BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

Therapeutic Potential of Natural Pharmacological Agents in the Treatment of Human Diseases

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 606021 | https://doi.org/10.1155/2014/606021

Parveen Kumar, Uma Bhandari, Shrirang Jamadagni, "Fenugreek Seed Extract Inhibit Fat Accumulation and Ameliorates Dyslipidemia in High Fat Diet-Induced Obese Rats", BioMed Research International, vol. 2014, Article ID 606021, 11 pages, 2014. https://doi.org/10.1155/2014/606021

Fenugreek Seed Extract Inhibit Fat Accumulation and Ameliorates Dyslipidemia in High Fat Diet-Induced Obese Rats

Academic Editor: Kota V. Ramana
Received28 Feb 2014
Revised08 Apr 2014
Accepted08 Apr 2014
Published29 Apr 2014

Abstract

This study investigated the inhibitory effect of aqueous extract of Trigonella foenum-graecum seeds (AqE-TFG) on fat accumulation and dyslipidemia in high fat diet- (HFD-) induced obese rats. Female Wistar rats were fed with HFD ad libitum, and the rats on HFD were treated orally with AqE-TFG or orlistat ((HFD for 28 days + AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) from day 8 to 28), respectively. Treatment with AqE-TFG produced significant reduction in body weight gain, body mass index (BMI), white adipose tissue (WAT) weights, blood glucose, serum insulin, lipids, leptin, lipase, and apolipoprotein-B levels and elevation in adiponectin levels. AqE-TFG improved serum aspartate amino transferase (AST), alanine amino transferase (ALT), and lactate dehydrogenase (LDH) levels. AqE-TFG treatment reduced the hepatic and cardiac thiobarbituric acid reactive substances (TBARS) and elevated the antioxidant enzyme (glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT)) levels. In addition, liver and uterine WAT lipogenic enzyme (fatty acid synthetase (FAS) and glucose-6-phosphate dehydrogenase (G6PD)) activities were restored towards normal levels. These findings demonstrated the preventive effect of AqE-TFG on fat accumulation and dyslipidemia, due to inhibition of impaired lipid digestion and absorption, in addition to improvement in glucose and lipid metabolism, enhancement of insulin sensitivity, increased antioxidant defense, and downregulation of lipogenic enzymes.

1. Introduction

Obesity is a chronic disorder of carbohydrate and lipid metabolism and is characterized by an increased fat deposition in adipose tissue and other internal organs [1]. Obesity leads to the development of insulin resistance, type-2 diabetes, coronary heart disease, cancer, respiratory disease, and osteoarthritis [2]. During the past 3-4 decades, changes in the food system seem to be the major drivers of the rise of the global epidemic of obesity [3]. As per the World Health Organization (WHO), in 2008, more than 1.4 billion adults (20 years of age and older) were overweight and amongst these over 200 million men and nearly 300 million women were obese [4].

Over the years, many medications have been used to manage obesity but most of them are now withdrawn due to their serious adverse effects [5]. Currently, orlistat is the only Food and Drug Administration (FDA) approved drug for long term management of obesity but this drug has undesirable gastrointestinal side effect such as steatorrhea [6]. In the face of this unmet medical need, there is requirement of new potential antiobesity drug to combat this syndrome.

Fenugreek (Trigonella foenum-graecum L.; TFG) belongs to the family Fabaceae and is used in many parts of the world for the treatment of diabetes. TFG seeds are used as an active ingredient in weight loss and anticholesterol ayurvedic formulation Ayurslim (The Himalaya Drug Company, Bangalore, India). TFG seeds have been shown to possess hypoglycemic, hypolipidemic, and antioxidant effects [7].

Dietary supplemented protein and amino acids have been shown to reduce plasma lipid levels [8, 9]. The presence of proteins and fiber in TFG seeds offers high nutritive value as it contains approximately 26% protein and 48% fiber and might exert a lipid lowering effect [10]. Dietary fibers (galactomannan) in fenugreek seeds are polysaccharides consisting of a mannose backbone with galactose side chains attached at position C6. Galactomannan consist of linear chains of (1–4) diequatorially linked D-mannose residues; some contain single-sugar side chains of D-galactose attached by (1–6) glycosidic bonds [11]. Fenugreek galactomannan form a viscous gel in the intestine and inhibit glucose and lipid absorption [12].

Oxidative stress is a biochemical disequilibrium occurring due to enhanced generation of reactive oxygen species (ROS). Elevated oxidative stress could be responsible for the initiation of metabolic disorders due to alterations in the membrane lipids and proteins [13]. In epidemiological studies, polyphenol and flavonoids-rich extract have been shown to possess the hypocholesterolaemic effect due to their antioxidant defense [14].

As plant proteins, dietary fiber and polyphenols do possess health benefits in metabolic disorders; therefore, in the present study, the inhibitory effect fenugreek extract was evaluated on fat accumulation and dyslipidemia in high fat diet-induced obese rats.

2. Materials and Methods

2.1. Plant Materials and Preparation of Extract

Trigonella foenum-graecum seeds were purchased from Indian Council for Agricultural Research (ICAR), New Delhi, India (ref. NISCAIR/RHMD/Consult/-2011-12/1743/43). The seeds were dried at 40°C and ground to a powder. The aqueous extract of Trigonella foenum-graecum seeds (AqE-TFG) was prepared as follows: powdered seeds were soaked in hot distilled water (1 : 20 w/v) and left overnight. The solution was filtered and lyophilized.

2.2. Electrophoretic Fingerprinting of Proteins in AqE-TFG

AqE-TFG was dissolved in phosphate buffer saline (PBS; pH 7.4; 1 : 10 w/v) and centrifuged (15,000 ×g, 30 min). The clear supernatant was dialyzed against PBS at 4°C (5000 cutoff membrane; with fresh buffer changes every 6 h, 4 times). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis was carried out as described by Laemmli [15], using 12% resolving gel and 5% stacking gel. Protein bands were stained with Coomassie Brilliant Blue R-250 in methanol-acetic acid-water (5 : 1 : 5 v/v/v) and decolorized in 7% acetic acid. Molecular weight of different bands was calibrated with the standard proteins markers: phosphorylase b (molecular weight, 97.4 kDa), albumin (66.2 kDa), ovalbumin (45 kDa), carbonic anhydrase (29 kDa), trypsin inhibitor (20.1 kDa), and -lactalbumin (14.4 kDa).

2.3. Amino Acid Analysis from AqE-TFG

The precolumn derivatisation of amino acid in AqE-TFG was performed with 6-aminoquinolyl-N-hydroxyl succinimidyl carbamate (AQC) and the concentration of amino acid was analysed by reverse phase high performance liquid chromatography (HPLC) (Waters Co., Milford, MA, USA). The excitation and emission wavelengths for fluorescence detector were 250 nm and 395 nm, respectively. The gain setting of the detector was 1, and the 5 μL of samples was injected onto Inertsil ODS-3V column ( mm, 4 μm) with the temperature controlled at 37°C and operated with a flow rate of 1.0 mL/min. The linear gradient elution system was used. Mobile phases A, B, and C were acetate buffer (pH 5.05) solution, acetonitrile, and water, respectively. The linear gradient conditions of solvents were modified as follows: initial, 100% A (acetate buffer); 0.5 min, 99% A, 1% B (HPLC grade acetonitrile); 18 min, 95% A, 5% B; 29.5 min, 83% A, 17% B; 33 min, 60% B, 40% C (Milli-Q water); 36 min, 100% A; 65 min, 60% B, 40% C; and 100 min, 60% B, 40% C.

2.4. Determination of Galactomannan in AqE-TFG

AqE-TFG was solubilized in water (1 : 20, w/v) at 4°C for 3 hours and centrifuged (16,000 ×g, 30 min). The supernatant was mixed with absolute ethanol (1 : 1, v/v) to precipitate galactomannan [12].

2.5. Determination of Phenolic and Flavonoid Contents in AqE-TFG

Phenolic contents of the extract were determined as follows: 50 μL aliquot of extract was assayed with 250 μL of Folin-Ciocalteu reagent and 500 μL of sodium carbonate (20%, w/v). The mixture was vortexed and diluted with water to a final volume of 5 mL. After incubation for 30 min at room temperature, the absorbance was read at 765 nm [16].

Flavonoid contents of the extract were determined as follows: 0.5 mL of sample; 0.5 mL of 2% AlCl3 (w/v) in 95% ethanol solution was added. After 1 h at room temperature, the absorbance was measured at 420 nm [17].

2.6. Experimental Design

The guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India, were followed and prior permission was sought from the Institutional Animal Ethics Committee (IAEC), Hamdard University (registration number 173/CPCSEA; protocol number 773), New Delhi, India, for conducting the study.

The female Wistar rats (150–200 g) were housed in polypropylene cages under controlled conditions (room temperature °C, air humidity %, and photoperiod of 12 h light: dark cycle), and water was provided ad libitum throughout the study. After acclimatization to the environment for one week, the animals were randomly divided into 5 groups ( rats in each group). Normal control rats (Group 1) were fed with normal pellet diet (NPD), while the others (Groups 2, 3, 4, and 5) were fed with high fat diet (HFD) ad libitum for 28 days. From day 8 to 28, Groups 3 and 4 were treated with AqE-TFG (0.5 and 1.0 g/kg body weight (b.w.), orally) while Group 5 was treated with orlistat (10 mg/kg b.w., orally). The solutions of AqE-TFG and orlistat were freshly prepared using normal saline. The compositions of NPD (Amrut rat feed, Mfd. by Nav Maharashtra Chakan Oil Mills Ltd., Delhi, India) and HFD (National Institute of Nutrition, Hyderabad, India) are shown in Table 1.


IngredientsNPDHFD

Casein212.0342.0
L-cystine3.03.0
Starch439.0172.0
Sucrose100.0172.0
Cellulose50.050.0
Ground nut oil25.0
Tallow190.0
Maltodextrin100.0
Soya bean oil50.0
AIN salt mix35.035.0
AIN vitamin mix10.010.0

Total (g)999.0999.0

2.7. Collection of Serum and Tissues

On day 29, blood was collected from the retroorbital plexus of overnight fasted rats under light ether anaesthesia and serum was separated by centrifugation at 3000 rpm for 15 min. Then, the rats were sacrificed. The organs (heart and liver) and white adipose tissue (WAT) (mesenteric, gonadal, and retroperitoneal) were excised, rinsed in ice-cold physiological saline, and weighed. The serum and organ samples were stored at C until analysis.

2.8. Determination of Anthropometric Parameters

Body weight gain was calculated as a difference of initial and final weight of animals. Body mass index (BMI) was calculated from the formula BMI = body weight (Kg)/length2 (m2) [18]. Food and water intakes were measured daily for a period of 28 days and the average of food and water consumption was calculated. Blood pressure (systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP)) and heart rate (HR) were measured with a noninvasive blood pressure recorder using the rat tail-cuff method (Kent Scientific Corporation).

2.9. Determination of Serum Biochemistries

The blood glucose, serum triglycerides (TGs), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) concentrations, aspartate amino transferase (AST), and alanine amino transferase (ALT) activities were assayed by enzymatic methods using commercial assay kits (Span Diagnostics Ltd., Surat, India) according to the manufacturer’s protocol. The serum lactate dehydrogenase (LDH) concentration was determined using an enzymatic kit (Reckon Diagnostics Pvt. Ltd., Baroda, India). Rat insulin immunoassay ELISA kit (Crystal Chem, Inc., IL, USA), rat leptin immunoassay ELISA kit (Ray Biotech Inc., GA, USA), rat adiponectin EIA kit (Ray Biotech Inc., GA, USA), apo-B immunoturbidimetric immunoassay kit (Randox Laboratories Ltd., UK), and lipase kit (BioAssay Systems, CA, USA) were used to measure the serum insulin, leptin, adiponectin, apo-B, and lipase concentrations.

Low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) levels were estimated using Friedewald’s equation: LDL-C=TC−HDL-C−VLDL-C; VLDL-C = TGs/5 [19]. The atherogenic index (AI) and coronary risk index (CRI) were calculated as log (TG/HDL-C) [20] and TC/HDL-C [21], respectively.

Homeostasis model assessment for insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated as fasting glucose (mg/dL) × fasting insulin (μU/mL)/2430 [22] and 1/[log insulin (μU/mL) + log glucose (mg/dL)] [23], respectively.

2.10. Determination of Tissue Biochemistries

The thiobarbituric acid reactive substances (TBARS) [24] and antioxidant enzymes activities, that is, reduced glutathione [25], superoxide dismutase (SOD) [26], and catalase (CAT) [27], were measured in hepatic and cardiac tissues. The fatty acid synthase (FAS) [28] and glucose-6-phosphate dehydrogenase (G6PD) [29] activities were assayed in hepatic and uterine WAT.

2.11. Histopathological Analysis

For histological examination, the liver tissue was collected, fixed in 10% neutral buffered formalin, and embedded in paraffin. Standard sections of 5 μm thickness were cut and stained with hematoxylin and eosin (H & E). The slides were examined by light microscopy.

2.12. Statistical Analysis

The data are expressed as means S.E.M. All statistical analyses were performed using Graph-Pad InStat version 3.06 (Graph Pad Software). All data were analyzed using 1-way analysis of variance (ANOVA) followed by Dunnett’s test. Results were considered statistically significant when .

3. Results

3.1. Chemical Compositions of AqE-TFG

The electrophoretic fingerprinting of AqE-TFG revealed that AqE-TFG contains proteins of molecular weight from 14.4 kDA to 97.4 kDA wherein thick protein bands lie <66.2 kDA (Figure 1). The contents of amino acid, phenolic, flavonoid, and galactomannan in AqE-TFG are summarized in Table 2.


CompositionsAqE-TFG

Amino acids (mg/g)Aspartic acid24.30
Serine13.70
Glutamic acid30.50
Glysine04.00
Histidine32.40
Arginine42.20
Threonine16.70
Alanine07.70
Proline10.70
Cystine27.50
Tyrosine08.80
Valine07.60
Methionine02.60
Lysine03.10
Isoleucine09.50
Leucine13.10
Phenylalanine10.40
Tryptophan04.90
Galactomannan (%; w/w)32.5
Phenolic contents (mg/g)
Flavonoid contents (mg/g)

3.2. Effect of AqE-TFG on Anthropometric Parameters

The feeding of HFD for 28 days caused a significant () increase in body weight gain and BMI of rats, in comparison with the NPD control rats. Treatment with AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) for 21 days significantly ( or ) suppressed the increase in the body weight gain and BMI of HFD-fed rats. Despite variation in body weight gain and BMI, there was no significant difference in food intake and water intake amongst all groups (Table 3).


GroupsBody weight gain (g)Food intake (g/day)Water intake (mL/day)BMI (kg/m2)Adiposity index (%)

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD+ AqE-TFG (1 g/kg)
HFD + orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.

A statistically significant () increase in SBP, DBP, and MAP was observed in the HFD control group than those in NPD group. AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) treatment significantly () decreased the elevated SBP, DBP, and MAP in HFD-fed rats (Table 4).


GroupsHR (beats/min)SBP (mm Hg)DBP (mm Hg)MAP (mm Hg)

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)
HFD + orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.

The weights of WAT (mesenteric, gonadal, and retroperitoneal) and organ (heart and liver) were significantly () higher in HFD control group than those in NPD group. AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) treatment significantly ( or ) lowered the WAT as well as organ weights when compared to the HFD control group (Table 5).


GroupsOrgan’s weight (g)WAT weight (g)
HeartLiverMesentericGonadalRetroperitoneal

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)
HFD + orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.
3.3. Effect of AqE-TFG on Serum Biochemistries

Table 6 represents the lipid profile of experimental rats. Rats in HFD control group displayed a significant () increase in the levels of TC, TGs, LDL-C, and VLDL-C and a significant () decrease in HDL-C in comparison with NPD group. Similar with the orlistat-treated HFD-fed group, AqE-TFG (0.5 and 1.0 g/kg) administration showed a significant () decrease in the levels of serums TC, TGs, LDL-C, and VLDL-C or a significant increase in the level of HDL-C after 21-day treatment when compared with HFD control group. The cardiac risk indexes (AI and CRI) were significantly () increased in HFD control group when compared to NPD group, while treatment with AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) caused a significant reduction in the AI and CRI levels compared to HFD control group.


GroupsTC (mg/dL)TG (mg/dL)HDL-C (mg/dL)LDL-C (mg/dL)VLDL-C (mg/dL)AICRI

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)
HFD + Orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.

The HFD-induced obese rats exhibited a significant () increase in the levels of blood glucose, serum insulin, leptin, apo-B, and HOMA-IR as compared to NPD-fed rats. After AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) treatment for 21 days, the increases of blood glucose, serum insulin, leptin, apo-B, and HOMA-IR were significantly brought down towards normal in HFD-fed rats (Table 7).


GroupsLeptin (ng/mL)Glucose (mg/dL)Insulin ( U/mL)HOMA-IRQUICKIApo-B (mg/dL)Adiponectin (ng/mL)

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)
HFD + orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.

A statistically significant () decrease in adiponectin levels and QUICKI was observed in the HFD control group than those in NPD group. AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) treatment significantly () elevated the reduced levels of adiponectin and QUICKI compared to HFD control group (Table 7).

The serum lipase, LDH, AST, and ALT levels were significantly () increased in HFD control group, when compared to the NPD group. A significant () reduction in lipase, LDH, AST, and ALT was observed in AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) treated group in comparison to the HFD control group (Table 8).


GroupsLipase (U/L)LDH (IU/L)AST (IU/L)ALT (IU/L)

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)
HFD + orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.
3.4. Determination of Tissue Biochemistries

Table 9 represents the lipogenic enzyme activities of the hepatic and uterine WAT. The HFD control group showed a significant () elevation in levels of lipogenic enzyme (FAS and G6PD) as compared to the NPD control group. Treatment with AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) for a period of 21 days caused a significant () reduction in levels of FAS and G6PD, respectively, as compared to the HFD control group.


GroupsFAS ( mol/min/g tissue)G6PD ( mol/min/g tissue)
LiverUterine WATLiverUterine WAT

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)
HFD + orlistat (10 mg/kg)

Results are expressed as mean ± S.E.M. ( ); compared to normal control; and compared to HFD control.

Table 10 represents the oxidative stress marker in hepatic and cardiac tissue. A marked increase of TBARS production and decrease of antioxidant enzyme status (GSH, SOD, and CAT) were observed in the hepatic and cardiac tissue of rats in HFD control group when compared with NPD group. AqE-TFG or orlistat treatment significantly () decreases the TBARS levels and raises the antioxidant enzyme (GSH, SOD, and CAT) activity.


GroupsTBARS
(nmol/mg protein)
GSH ( mol of P liberated/
min/mg protein)
SOD
(U/mg protein)
CAT
(nmol of H2O2/min/mg protein)
LiverHeartLiverHeartLiverHeartLiverHeart

Normal control
HFD control
HFD + AqE-TFG (0.5 g/kg)
HFD + AqE-TFG (1 g/kg)